Rua completes first step to Polish market entry

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE
NZX Limited
Wellington

Thursday, 6 April 2023

Rua completes first step to Polish market entry

Rua Bioscience (NZX:RUA) is pleased to announce that its first medicinal cannabis dossier for the Polish market
has now been submitted to the regulatory authority responsible for licencing cannabis-based medicines in
Poland (the Polish Office for Registration of Medicinal Products (URPL)).

The dossier, prepared by the regulatory team from Rua and its Australian manufacturing partner Cann Group,
provides detailed information to demonstrate the quality of the product, including information about the
cultivation of the cannabis, and the subsequent manufacturing process, quality checks and stability of the
product.

The submission of the dossier is the first step in accessing the high-value Polish market, triggering what is
anticipated to be a highly complex, but ultimately rewarding, 12- to 18-month process.

The Polish medicinal cannabis market was established in 2017 and is described as one of the largest and
fastest-growing markets in Europe. The market shows consistent double-digit growth and, according to
proprietary data, could be worth NZ$92m by the close of 2023.

Rua Bioscience CEO, Paul Naske, says “Poland is a very tricky market to enter, but presents significant
opportunity for those with access. Our work with the specialist sales and marketing team at Motagon has
positioned us as an early mover, and we expect their European-based support and regulatory expertise will be
invaluable as we progress our submission.”

Last week, Rua announced it would accelerate its export-focused strategy investigating the commercial
potential of markets such as Poland, Czechia, the United Kingdom, and Australia.

“As we enter high-value international markets, steps like this will become more commonplace. But the
submission of our first dossier in Poland demonstrates a tangible commitment to our export strategy and to
create a sustainable international business.”

Ends

This announcement is authorised by:
Paul Naske
Chief Executive Officer, Rua Bioscience


For shareholder enquiries please visit www.ruabio.com, or contact:
Hamish White
Chief Financial Officer, Rua Bioscience
Hamish.white@ruabio.com

GENERAL ANNOUNCEMENT